DOC Healthpeak Properties
Outpatient medical annuity at a ~7.8% AFFO yield; lab glut and rates explain the discount, not justify it.
The story
Healthpeak owns a roughly $20B+ portfolio split across outpatient medical (the largest, steadiest segment after the Physicians Realty merger), lab/life science concentrated in South San Francisco, Boston and San Diego, and CCRC/senior housing. Outpatient medical demand rides aging demographics and the shift of care to outpatient settings, while lab faces a supply glut and weak biotech funding that keeps occupancy and re-leasing spreads under pressure. The balance sheet is investment grade (BBB+) at about 5.2x net debt/EBITDA with mostly fixed-rate debt. Even so, the stock trades like a long-duration bond and reprices with the 10-year. FFO of about $1.88/share on a $18.80 price is roughly a 10x multiple and a ~7.8% AFFO yield.
I trimmed Y1 growth from 4% to 3% because the 10% price drop since August, flat recent FFO guidance and continued lab leasing weakness suggest same-store growth in outpatient medical (about 3%) is being offset by lab occupancy drag; nothing structural changed, so the other drivers stay. AFFO/FFO stays at 0.78 because lab TI/leasing costs and medical office capex are heavy. Beta of 0.92 and 3% failure risk reflect an investment-grade, diversified healthcare landlord with real rate sensitivity. The baseline's $32 overstates value because it ignores the recurring capex haircut; on AFFO my value lands in the low-to-mid $20s, a 20-30% gap to market that the lab overhang explains.
Value drivers
| AFFO growth (Y1) | 3.0% |
| Terminal AFFO growth | 2.5% |
| AFFO / FFO ratio | 78.0% |
| Beta | 0.92 |
| Failure probability | 3.0% |
| Cost of equity | 9.4% |
Valuation bridge
| PV of AFFO (explicit) | 7.36B |
| PV of terminal value | 8.10B |
| Equity value | 15.00B |
| ÷ shares → per share | $21.75 |
Projected AFFO
| Yr | FFO | AFFO | Growth | PV |
|---|---|---|---|---|
| 1 | 1.34B | 1.05B | 3.0% | 957.81M |
| 2 | 1.38B | 1.08B | 2.9% | 901.43M |
| 3 | 1.42B | 1.11B | 2.9% | 847.90M |
| 4 | 1.46B | 1.14B | 2.8% | 797.12M |
| 5 | 1.50B | 1.17B | 2.8% | 748.98M |
| 6 | 1.54B | 1.20B | 2.7% | 703.37M |
| 7 | 1.59B | 1.24B | 2.7% | 660.17M |
| 8 | 1.63B | 1.27B | 2.6% | 619.29M |
| 9 | 1.67B | 1.30B | 2.6% | 580.63M |
| 10 | 1.71B | 1.33B | 2.5% | 544.09M |
Key risks
- Lab oversupply and weak biotech funding push occupancy and rents down longer than expected
- Higher-for-longer rates compress REIT multiples and raise refinancing costs on 2027-2028 maturities
- Tenant credit stress among small-cap biotechs and health-system operators, plus CCRC operating volatility
Catalysts
- Lab leasing inflection and stabilization of South San Francisco occupancy as biotech funding recovers
- Fed cuts lowering the 10-year, plus buybacks or accretive outpatient medical development deliveries